A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
|Articles|June 19, 2009
Oncology NEWS International
- Oncology NEWS International Vol 18 No 6
- Volume 18
- Issue 6
Abraxis backs SPARC as prognostic biomarker
SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.
Advertisement
SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.
Researchers at Abraxis BioScience, the manufacturer of Abraxane (nab-paclitaxel), found that recombinant human SPARC grown in vitro fostered angiogenesis and the development of mature blood vessels. SPARC may play a greater role in the angiogenic process beyond initiating the growth of new blood vessels, they said (abstracts 1478, 2572, 3769, 4017, 5168).
Articles in this issue
over 17 years ago
ADT in prostate ca increases risk of bone and heart complicationsover 17 years ago
ALK-1 receptor: New target in angiogenesisover 17 years ago
Abraxane prolongs PFS in metastatic diseaseover 17 years ago
SAVI applicator removes obstacles associated with brachytherapyover 17 years ago
Mistrust, costs reduce breast cancer screening among minoritiesover 17 years ago
Oral chemotherapy poses more challenges for cancer communityover 17 years ago
CMS nixes CT colonography screeningover 17 years ago
New ultrasound strategy helps pinpoint prostate tumorsAdvertisement
Related to this article
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
3
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5